Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, October 31, 2012 ONYX PHARMACEUTICALS, INC. (NASDAQ:ONXX), Up By 8.03% ($6.42) From $79.884 After BUYINS.NET Report Predicted Strength After Ear
October 31, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Monday, October 29th 2012 stating that ONYX PHARMACEUTICALS, INC. (NASDAQ:ONXX) was expected to be Up After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=onxx&id=322985
At the time this story was written, ONYX PHARMACEUTICALS, INC. (NASDAQ:ONXX) is Up By 8.03% ($6.42) From $79.884 since the BUYINS.NET report was released.
The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php
ONYX PHARMACEUTICALS, INC. (NASDAQ:ONXX) - Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally. Its lead product includes Nexavar (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in tumor cell proliferation and angiogenesis. This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals. Its developing products include Nexavar for the treatment of liver cancer, kidney cancer, non-small cell lung cancer, thyroid cancer, breast cancer, ovarian cancer, and colorectal cancer; and Carfilzomib for the treatment of multiple myeloma and solid tumor. The company also develops ONX 0801, a Phase 1 clinical stage product, under a development and license agreement with BTG International Limited; and ONX 0912, an oral proteasome inhibitor. In addition, it develops ONX 0914, a preclinical stage product for the treatment of autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease, and lupus. In addition, Onyx Pharmaceuticals, through a development collaboration, option, and license agreement with S*BIO Pte Ltd, owns options to license the rights of ONX 0803 and ONX 0805. ONX 0803 is an orally available, potent, and selective inhibitor of JAK2; and ONX 0805 is a JAK2 inhibitor. Further, the company has a research and development collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore the control of, or otherwise intervene in, the misregulated cell cycle in tumor cells. Onyx Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Emeryville, California..
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. ONYX PHARMACEUTICALS, INC. (NASDAQ:ONXX) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
- WOPRAI
- support@woprai.com